A Clinical Trial of P134 Cells in Recurrent Glioblastoma

Clinical trial NCT07318818 · RECRUITING

Trial details

NCT number: NCT07318818
Sponsor: Tasly Pharmaceutical Group Co., Ltd
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent Glioblastoma IDH Wildtype

Start date: 2026-01-05
Primary completion: 2028-02-29
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.